AADI vs. SOPH, ATYR, DSGN, IMMP, ELDN, CTNM, YMAB, HRTX, ITOS, and AQST
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include SOPHiA GENETICS (SOPH), Atyr PHARMA (ATYR), Design Therapeutics (DSGN), Immutep (IMMP), Eledon Pharmaceuticals (ELDN), Contineum Therapeutics (CTNM), Y-mAbs Therapeutics (YMAB), Heron Therapeutics (HRTX), iTeos Therapeutics (ITOS), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.
Aadi Bioscience vs.
SOPHiA GENETICS (NASDAQ:SOPH) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
Aadi Bioscience has lower revenue, but higher earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
SOPHiA GENETICS has a net margin of -110.71% compared to Aadi Bioscience's net margin of -246.06%. SOPHiA GENETICS's return on equity of -55.06% beat Aadi Bioscience's return on equity.
SOPHiA GENETICS has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.
SOPHiA GENETICS presently has a consensus price target of $7.40, suggesting a potential upside of 103.86%. Aadi Bioscience has a consensus price target of $1.67, suggesting a potential downside of 38.95%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, research analysts plainly believe SOPHiA GENETICS is more favorable than Aadi Bioscience.
31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Aadi Bioscience had 6 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 6 mentions for Aadi Bioscience and 0 mentions for SOPHiA GENETICS. Aadi Bioscience's average media sentiment score of 1.09 beat SOPHiA GENETICS's score of 0.50 indicating that Aadi Bioscience is being referred to more favorably in the news media.
SOPHiA GENETICS received 8 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 73.08% of users gave SOPHiA GENETICS an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote.
Summary
SOPHiA GENETICS beats Aadi Bioscience on 12 of the 18 factors compared between the two stocks.
Get Aadi Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aadi Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:AADI) was last updated on 2/5/2025 by MarketBeat.com Staff
